comparemela.com

Latest Breaking News On - அல்லாத ஆல்கஹால் கொழுப்பு கல்லீரல் நோய் - Page 17 : comparemela.com

INVENTIVA: Full-Year 2020: Cash position and revenues

Cash position2 at €113.0m as of December 31, 2020 compared to €124.6 million at September 30, 2020 and €35.8 million at December 31, 2019Revenues of €0.4m in 2020 compared to €7.0m in 2019Successful €94.9m3

Global Liver Institute Releases Comprehensive U S NASH Action Plan

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Global Liver Institute Releases Comprehensive U.S. NASH Action Plan Global Liver InstituteFebruary 9, 2021 GMT Washington, DC, Feb. 09, 2021 (GLOBE NEWSWIRE) Global Liver Institute (GLI) and the GLI NASH Council have released the U.S. NASH Action Plan to comprehensively address nonalcoholic steatohepatitis (NASH), the advanced form of nonalcoholic fatty liver disease (NAFLD), and its impact on patients and families, public health, and the economy. It is estimated that up to 40 million people in the U.S.,(1) including 10% of American children,(2)(3)(4) are living with NASH, which can progress into cirrhosis or liver cancer, among a number of conditions, and potentially require a liver transplant. GLI’s new plan includes a set of actionable recommendations for the full spectrum of groups involved in NASH prevention and treatment, including: patients and caregivers, clinicians, patient

iBiopsy: Median Technologies Inks a Major Research Collaboration Agreement With the University of California San Diego (UC San Diego)

(1) The research collaboration agreement covers a joint clinical retrospective study on liver fibrosis severity in Non-Alcoholic Steato-Hepatitis (NASH) patients The collaboration will enable Median to work on a large NASH patient cohort to lead the validation of its iBiopsy s AI technology, applied to liver fibrosis characterization The Liver Center at UC San Diego is a world-renowned university and healthcare center for liver diseases, with a focus on Non-Alcoholic Fatty Liver Disease (NAFLD) NASH Regulatory News: Median Technologies (Paris:ALMDT) (ALMDT:PA) announces today the company has signed a research collaboration agreement with the University of California San Diego (UC San Diego) aimed at carrying out a study that will be used for its proprietary imaging platform iBiopsy validation. The study is related to the iBiopsy NASH Clinical Development Plan (CDP).

India s Next Sushruta—Fostering Novel Thinking In Healthcare

India s Next Sushruta Fostering Novel Thinking In Healthcare + We serve personalized stories based on the selected cityOK Hello, Subscribe Please enter valid email. Thank you for subscribing!Your subscription is confirmed for latest news across Entertainment, Television and Lifestyle newsletters. Comments () Help us delete comments that do not follow these guidelines by marking them offensive. Let s work together to keep the conversation civil. Be the first one to review. We have sent you a verification email. To verify, just follow the link in the message India s Next Sushruta Fostering Novel Thinking In Healthcare By - facebook Pintrest Healthcare has evolved to become a field that is driven by values of dispensing the best possible patient care, on the back of technological innovations and a sensitive approach. Young aspiring doctors in the country, eager to play their part in cultivating a culture that encourages inventive thinking, came toge

Cadila Healthcare Ltd Q3FY21 consolidated net profit higher at Rs 527 2 crore

Cadila Healthcare Ltd Q3FY21 consolidated net profit higher at Rs. 527.2. crore Posted On: CADILA HEALTHCARE LTD. has reported financial results for the period ended December 31, 2020. Financial Results (Q3 FY20-21) - QoQ Comparison The company has reported total income of Rs.3823.1 crores during the period ended December 31, 2020 as compared to Rs.3847.5 crores during the period ended September 30, 2020. The company has posted net profit / (loss) of Rs.527.2 crores for the period ended December 31, 2020 as against net profit / (loss) of Rs.473.4 crores for the period ended September 30, 2020. The company has reported EPS of Rs.5.15 for the period ended December 31, 2020 as compared to Rs.4.62 for the period ended September 30, 2020.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.